Vigil Neuroscience (VIGL) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

VIGL Vigil Neuroscience

Watchlist

1.990
-0.010-0.50%

Close Dec 13 16:00 ET

81.35MMarket Cap-0.96P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Purchase: President and CEO of $VIGL (VIGL) Buys 5,000 Shares
Quiver QuantitativeDec 5 17:17 ET
William Blair Initiates Vigil Neuroscience at Outperform
MT NewswiresDec 4 08:17 ET
William Blair Initiates Coverage On Vigil Neuroscience With Outperform Rating
BenzingaDec 4 03:20 ET
Optimistic Buy Rating for Vigil Neuroscience Amid Market Overreaction
TipRanksNov 27 01:05 ET
Guggenheim Maintains Vigil Neuroscience(VIGL.US) With Buy Rating
Moomoo NewsNov 26 12:31 ET · Ratings
Express News | JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Announces $22 Price Target
BenzingaNov 26 08:01 ET

Comments

Trytosaveabit

Oct 9 17:50

Form 13

$Vigil Neuroscience (VIGL.US)$ Vigil Neuroscience | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Vida Ventures GP III, L.L.C.(12.7%),Stefan Vitorovic(12.7%), etc.
SEC· 21 mins ago

TheOracleOfBroMaha

Sep 19 10:17

$Vigil Neuroscience (VIGL.US)$ JMP Buy Rating Target $23

Jaguar8

Sep 17 06:03

NEWS

$Vigil Neuroscience (VIGL.US)$
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
Vigil Neuroscience (Nasdaq: VIGL) announced that the FDA has removed the partial clinical hold on its Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease. The decision was based on non-clinical and clinical data from the ongoing trial. Interim data from July 2024 showed a favorable safety and tolerability profile, predictable pharmacokinetics supporting once-daily ...

Jaguar8

Jul 24 14:20

NEWS

$Vigil Neuroscience (VIGL.US)$
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
Vigil Neuroscience (Nasdaq: VIGL) has announced promising interim data from its ongoing Phase 1 clinical trial of VG-3927, a potential once-daily oral therapy for Alzheimer's disease (AD).
The trial, which has enrolled 80 healthy volunteers, demonstrated a favorable safety and tolerabi...

Seraphicall

Jul 20 02:25

Looking good

$Vigil Neuroscience (VIGL.US)$

Heat List

Overall

No Data